Skip to content
value.today

enGene Therapeutics Inc.

ENGN
$105 Mmarket cap on Oct 15, 2026
1D
-8.2%
Compare
World rank
#18,572
Revenue
—
For year ending October-2025
Net income
$-117 M
SEC filing
Employees
82
As of October 31, 2025
SEC filing

enGene Therapeutics Inc. in brief

enGene Therapeutics Inc. is a listed company in the Biotechnology industry, based in Canada. Its market value was $105 M on 15 October 2026, which makes it the 18,572nd largest listed company in the world and the 694th largest in Canada on this site. It employs about 82 people. Its shares trade under the symbol ENGN (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About enGene Therapeutics Inc.

enGene Holdings Inc. formed in connection with the Merger Agreement (as defined below), was incorporated as 14963148 Canada Inc. under the federal laws of Canada on April 24, 2023 and changed its name to enGene Holdings Inc. on May 9, 2023. On October 31, 2023, enGene Holdings Inc. continued from being a corporation incorporated under and governed by the Canada Business Corporations Act to a company continued to and governed by the Business Corporations Act (British Columbia).

Forbion European Acquisition Corporation was a special purpose acquisition company, incorporated as a Cayman Island exempted company on August 9, 2021 and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more business or entities. On October 31, 2023, the Company, FEAC, and enGene Inc., a subsidiary of the Company, consummated the merger pursuant to a business combination agreement, dated as of May 16, 2023.

From the company's annual report filed with the US SEC: read the report

enGene Therapeutics Inc. timeline

3 events, 2022–2026
  1. 2022
  2. 🔔
    · approximate
    Initial public offering on Nasdaq
  3. 2023
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2026
  6. ✎
    Renamed enGene Therapeutics Inc.
    Formerly enGene Holdings Inc..

Events of enGene Therapeutics Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$31 M$62 M$92 M$123 M

World rank over time

▼ down 1,612 places since 2026
2026-08-01: #17002#17,00220262026-10-13: #18352#18,35220262026-10-15: #18614#18,6142026

Rank in Canada: #504 (Aug 2026) · #699 (Oct 2026) · #694 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.6×
Free cash flow yield
-96.3%
Net margin
—
Operating margin
—
Return on equity
-69.9%
Liabilities / assets
24.3%
Payout ratio
0.0%
Profit per employee
$-1.4 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Oct 2022: revenue —, net income $-24M—FY22Fiscal year ending Oct 2023: revenue —, net income $-100M—FY23Fiscal year ending Oct 2024: revenue —, net income $-55M—FY24Fiscal year ending Oct 2025: revenue —, net income $-117M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Oct 2025——$-123M$-117M—
Oct 2024——$-62M$-55M—
Oct 2023——$-26M$-100M—
Oct 2022——$-19M$-24M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Oct 2025$-99M$1M$-101M$2.29$0.00
Oct 2024$-48M$1M$-49M$1.46$0.00
Oct 2023$-25M$0M$-25M$151.22$0.00
Oct 2022$-18M$0M$-18M$44.30—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Oct 2024 (from the annual report): revenue —, net income $-15M—Oct ’24Three months to Jan 2025: revenue —, net income $-25M—Jan ’25Three months to Apr 2025: revenue —, net income $-26M—Apr ’25Three months to Jul 2025: revenue —, net income $-29M—Jul ’25Three months to Oct 2025 (from the annual report): revenue —, net income $-38M—Oct ’25Three months to Jan 2026: revenue —, net income $-30M—Jan ’26Three months to Apr 2026: revenue —, net income $-30M—Apr ’26Three months to Jul 2026: revenue —, net income $-33M—Jul ’26

Latest quarter to Jul 2026: revenue —, net income $-33M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jul 2026.

SEC filings

Official filings of enGene Therapeutics Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-123 M
Net income
$-117 M

For year ending October-2025 · source: SEC filing

Balance sheet

Total assets
$221 M
Total liabilities
$54 M
Total equity
$168 M

As of October-2025

Top 58 institutional investors in enGene Therapeutics Inc.#

As of Sep 30, 2026
58 institutions held 37.8 M shares (about 56.4% of the shares outstanding) on Sep 30, 2026. The ten largest hold 46.8%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in enGene Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BML Capital Management, LLC6,669,9080 (0.00%)9.95%$13 MNov 6, 2026
2Siren, L.L.C.6,256,6620 (0.00%)9.34%$13 MNov 12, 2026
3Acorn Capital Advisors, LLC3,811,782+2,540,525 (+199.84%)5.69%$8 MNov 16, 2026
4Perceptive Advisors LLC3,482,169-1,340,000 (-27.79%)5.20%$7 MNov 16, 2026
5Eventide Asset Management, LLC3,406,023New5.08%$7 MNov 13, 2026
6Nextech Invest Ltd.2,324,9430 (0.00%)3.47%$5 MNov 16, 2026
7Vestal Point Capital, LP1,665,000-2,430 (-0.15%)2.48%$3 MNov 16, 2026
8ADAR1 Capital Management, LLC1,329,986-775,000 (-36.82%)1.98%$3 MNov 16, 2026
9Two Sigma Investments, LP1,292,137+1,127,567 (+685.16%)1.93%$3 MNov 16, 2026
10Renaissance Technologies LLC1,134,400+304,700 (+36.72%)1.69%$2 MNov 12, 2026
11Peapod Lane Capital LLC1,038,617-63,532 (-5.76%)1.55%$2 MOct 22, 2026
12SR One Capital Management, LP747,750New1.12%$1 MNov 16, 2026
13Aldebaran Capital, LLC657,319New0.98%$1 MNov 13, 2026
14Flputnam Investment Management Co556,121New0.83%$1 MNov 13, 2026
15Kynam Capital Management, LP457,8550 (0.00%)0.68%$1 MNov 16, 2026
16Citadel Advisors LLC444,471-273,215 (-38.07%)0.66%$1 MNov 16, 2026
17Squarepoint Ops LLC299,747+84,366 (+39.17%)0.45%$1 MNov 9, 2026
18Jane Street Group, LLC291,730-90,729 (-23.72%)0.44%$1 MNov 12, 2026
19Rangeley Capital, LLC287,898-17,204 (-5.64%)0.43%$1 MNov 16, 2026
20Millennium Management LLC181,619-785,008 (-81.21%)0.27%$0 MNov 16, 2026
21D. E. Shaw & Co., Inc.170,408New0.25%$0 MNov 16, 2026
22Privium Fund Management B.V.170,0000 (0.00%)0.25%$0 MNov 3, 2026
23Gsa Capital Partners LLP127,975+90,629 (+242.67%)0.19%$0 MNov 16, 2026
24XTX Topco Ltd117,582-33,842 (-22.35%)0.18%$0 MNov 16, 2026
25Quadrature Capital Ltd100,069-138,966 (-58.14%)0.15%$0 MNov 13, 2026
Show all 58: investors 26 to 58
Institutional investors 26 to 58 in enGene Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Point72 Asset Management, L.P.75,552+61,560 (+439.97%)0.11%$0 MNov 16, 2026
27DAFNA Capital Management LLC74,6500 (0.00%)0.11%$0 MNov 16, 2026
28HRT Financial LP74,395+57,564 (+342.01%)0.11%$0 MNov 13, 2026
29Carlson Capital, L.P.50,000New0.07%$0 MNov 9, 2026
30Axq Capital, LP49,869New0.07%$0 MNov 12, 2026
31PFS Partners, LLC40,000+29,000 (+263.64%)0.06%$0 MOct 21, 2026
32Engineers Gate Manager LP39,522+12,236 (+44.84%)0.06%$0 MNov 16, 2026
33Dimensional Fund Advisors LP38,2910 (0.00%)0.06%$0 MNov 4, 2026
34Marshall Wace, LLP35,982New0.05%$0 MNov 13, 2026
35Spark Investment Management LLC30,800New0.05%$0 MNov 13, 2026
36Indivisible Partners29,446New0.04%$0 MOct 26, 2026
37Scientech Research LLC29,004-11,706 (-28.75%)0.04%$0 MNov 16, 2026
38Sectoral Asset Management Inc21,7000 (0.00%)0.03%$0 MNov 13, 2026
39Morgan Stanley21,685-11,401 (-34.46%)0.03%$0 MNov 13, 2026
40Covestor Ltd21,451New0.03%$0 MOct 30, 2026
41BNP Paribas Financial Markets20,486-4,933 (-19.41%)0.03%$0 MNov 12, 2026
42Graham Capital Management, L.P.19,933New0.03%$0 MNov 16, 2026
43Susquehanna International Group, LLP17,743-6,727 (-27.49%)0.03%$0 MNov 16, 2026
44Jpmorgan Chase & Co15,556New0.02%$0 MNov 12, 2026
45Obsidian Cio, LLC15,000New0.02%$0 MNov 5, 2026
46Virtu Financial LLC14,031+45 (+0.32%)0.02%$0 MNov 17, 2026
47Royal Bank Of Canada11,3250 (0.00%)0.02%$0 MNov 16, 2026
48Raymond James Financial Inc11,284-10,072 (-47.16%)0.02%$0 MNov 12, 2026
49Wells Fargo & Company/mn6,8400 (0.00%)0.01%$0 MNov 16, 2026
50UBS Group AG6,518-502,569 (-98.72%)0.01%$0 MNov 10, 2026
51Simplex Trading, LLC5,025+4,626 (+1159.40%)0.01%$0 MNov 4, 2026
52Citigroup Inc492New0.00%$0 MNov 4, 2026
53Wolverine Asset Management LLC278-2,686 (-90.62%)0.00%$0 MNov 2, 2026
54Tower Research Capital LLC (TRC)233New0.00%$0 MNov 16, 2026
55Group One Trading LLC215New0.00%$0 MNov 10, 2026
56Farther Finance Advisors, LLC1000 (0.00%)0.00%$0 MOct 8, 2026
57SBI Securities Co., Ltd.280 (0.00%)0.00%$0 MOct 22, 2026
58Aquatic Capital Management LLC21-8 (-27.59%)0.00%$0 MNov 16, 2026

Mutual funds holding enGene Therapeutics Inc.#

4 funds hold shares worth $0 M. Since their previous reports 1 added shares and 6 sold, selling $6 M net.
Mutual funds holding enGene Therapeutics Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC40,733$0 M—<0.01%+5.0%May 31, 2026
🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC10,639$0 M—<0.01%no changeJun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC9,974$0 M—<0.01%no changeJun 30, 2026
🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc.1,376$0 M—<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at enGene Therapeutics Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$10 K
1 purchase, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$10 K
open market only
Insiders on file
10
since
$5.5 M-$788 K$0Dec 2023: bought $149 K (4 trades), sold $0 (0 trades)Dec 23Apr 2024: bought $0 (0 trades), sold $788 K (3 trades)AprSep 2024: bought $2.5 M (4 trades), sold $0 (0 trades)SepOct 2024: bought $5.5 M (7 trades), sold $0 (0 trades)OctSep 2026: bought $10 K (1 trades), sold $0 (0 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
enGene Therapeutics Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed William GrossmanInterim Chief Medical Officer, DirectorBuy+5,102$1.970$10 K5,102Form 4
filed Forbion Growth Management B.V.10% ownerBuy+561,797$8.900$5.0 M3.03 MForm 4
filed Forbion Growth Opportunities Fund I Cooperatief U.A.10% ownerBuy+800$6.600$5 K2.47 MForm 4
filed Forbion Growth Opportunities Fund I Cooperatief U.A.10% ownerBuy+11,844$6.550$78 K2.47 MForm 4
filed Forbion Growth Opportunities Fund I Cooperatief U.A.10% ownerBuy+5,997$6.540$39 K2.46 MForm 4
filed Forbion Growth Opportunities Fund I Cooperatief U.A.10% ownerBuy+5,769$6.480$37 K2.45 MForm 4
filed Forbion Growth Opportunities Fund I Cooperatief U.A.10% ownerBuy+10,153$6.370$65 K2.45 MForm 4
filed Forbion Growth Opportunities Fund I Cooperatief U.A.10% ownerBuy+35,279$6.440$227 K2.44 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: enGene Therapeutics Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.6 M
3.1% of shares · 1.92 days to cover
Dividend per share, Q1 2026
$0.000
— on a year earlier
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-5.54 reverse split

enGene Therapeutics Inc. dividends per share by quarter
Dividend, quarterPer share
Q1 2026$0.000
Q1 2025$0.000
Q1 2024$0.000

Trading halts

  • 2025-11-11 15:08 UTC, code LUDP, resumed 15:13 UTC
  • 2025-11-11 15:02 UTC, code LUDP, resumed 15:07 UTC

Fails to deliver

  • : 9,142 shares at $1.56
  • : 75 shares at $1.70
  • : 4,517 shares at $1.78
  • : 6,255 shares at $1.75
  • : 1,738 shares at $1.80

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

enGene Therapeutics Inc. scorecard#

Passes 3 of the 11 checks that could be worked out. Fiscal year 2025; market cap of Oct 15, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.6×Price to book 0.6× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-96.3%Free cash flow is -96.3% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✓Earnings per share grew in the newest year2.29 vs 1.46Diluted EPS 2.29 in fiscal 2025 against 1.46 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$117 MNet income -$117 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-53.3%-53.3% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities6.3×Current ratio 6.30 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 2
    • ✗Pays a dividendNoNo dividends in fiscal 2025.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year35.3%Diluted shares up 35.3% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

enGene Therapeutics Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

enGene Therapeutics Inc.: statements by fiscal year
PeriodTrendFY 2025to Oct 31, 2025FY 2024to Oct 31, 2024FY 2023to Oct 31, 2023FY 2022to Oct 31, 2022
Income statement
Research and development94381615
General and administrative29249.64.0
Operating expenses123622619
Operating income−123−62−26−19
Interest and finance income9.4101.10.1
Interest expense and finance costs3.02.85.01.4
Other non-operating income (expense)5.97.1−74−5.0
Income before tax−117−55−100−24
Income tax0−0.00.00.0
Net income including minority interests−117−55−100−24
Net income attributable to shareholders−117−55−100−24
Earnings per share, basic2.291.46151.2244.30
Earnings per share, diluted2.291.46151.2244.30
Shares, weighted average (basic)51380.70.7
Shares, weighted average (diluted)51380.70.7
Dividends per share0.000.000.00—
Balance sheet
Cash and cash equivalents501738220
Short-term investments14465——
Other current assets6.68.61.50.7
Current assets2012478523
Property, plant and equipment2.51.20.60.4
Right-of-use (leased) assets7.71.7——
Total assets2213118724
Accounts payable6.71.41.20.7
Current liabilities32155.35.1
Lease liabilities (non-current)6.51.4——
Total liabilities54391447
Retained earnings−372−255−200−100
Shareholders' equity16827372−77
Total liabilities and equity2213118724
Shares outstanding5251230.7
Cash-flow statement
Depreciation and amortization0.50.30.20.2
Share-based compensation9.65.33.50.1
Cash from operating activities−99−48−25−18
Capital expenditure−1.5−0.9−0.3−0.2
Cash from investing activities−25−126−0.3−0.2
Debt issued—23—11
Debt repaid———−1.0
Dividends paid——0—
Cash from financing activities1.52668628
Exchange-rate effect on cash0.00.00.0−0.8
Change in cash−12391619.4
Report10-K10-K10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jul 31, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at enGene Therapeutics Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Restructuring 2 · Directors and officers 9 · Material agreement 5 · Agreement ended 1 · New debt 2 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8

enGene Therapeutics Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officers8-K
RestructuringDirectors and officers8-K/A
RestructuringDirectors and officersResults announced8-K
Shareholder vote8-K
Directors and officers8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Material agreementAgreement ended8-K
Material agreementNew debtUnregistered share sale8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K/A
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officersShareholder vote8-K
Material agreementNew debt8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Layoffs at enGene Therapeutics Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
2 notices and filings
People, all years
0
2026–2026
Latest
—
2026-06-16
enGene Therapeutics Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2026···········—
enGene Therapeutics Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
50% of workforceRestructuring planSEC 8-K“As previously disclosed in the Company’s Original Form 8-K, effective June 14, 2026, the Company’s board of directors (the “Board”) approved a plan to reduce the Company’s workforc…”Filing
50% of workforceRestructuring planSEC 8-K“On June 15, 2026, the Company announced the implementation of a plan to reduce its workforce by approximately 50% to streamline operations and preserve cash.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How enGene Therapeutics Inc. compares in Biotechnology

  • Market cap$105 M · higher than 37% of 726
  • Price / book0.6× · lower than 89% of 534
  • FCF yield-96.3% · higher than 10% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
enGene Therapeutics Inc.🇨🇦$105 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 15, 2026
Annual results:
For year ending October-2025
Balance sheet:
As of October-2025
Employees:
As of October 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at enGene Therapeutics Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show enGene Therapeutics Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about enGene Therapeutics Inc.? Suggest a correction